Ryan Christensen on Biogen Earnings Growth | NECN Market Analysis

Biogen Reports 15% Earnings Growth, 9% Revenue Gains

Ryan Christensen, account executive at Adviser Investments, has the market analysis for Tuesday, July 24. The Dow Jones Industrial Average and S&P 500 gained 0.8% and 0.5%, respectively, while the NASDAQ Composite declined fractionally. For earnings, we saw Biogen (ticker: BIIB) top expectations with 15% earnings per share growth and 9% revenue advances. BIIB closed the day up nearly 6%. Investors continue to react favorably to Biogen’s stock as the company is scheduled to present clinical trials on its experimental BAN2401 therapy at this week’s Alzheimer’s Association International Conference.

Recent Videos

View All Videos

Lowell on China’s Evergrande Debacle

Wiener on the ETF Edge Podcast

Wiener Talks China on CNBC

Lowell on Fox Business: Market Still Has Room to Run

Adviser Investments' logo is a registered trademark of Adviser Investments, LLC.